Logo image of HLTH

CUE HEALTH INC (HLTH) Stock Fundamental Analysis

NASDAQ:HLTH - Nasdaq - US2297901009 - Common Stock - Currency: USD

0.0434  -0.02 (-29.77%)

After market: 0.0489 +0.01 (+12.67%)

Fundamental Rating

3

Taking everything into account, HLTH scores 3 out of 10 in our fundamental rating. HLTH was compared to 189 industry peers in the Health Care Equipment & Supplies industry. HLTH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, HLTH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

HLTH had negative earnings in the past year.
In the past year HLTH has reported a negative cash flow from operations.
HLTH had negative earnings in 4 of the past 5 years.
In the past 5 years HLTH reported 4 times negative operating cash flow.
HLTH Yearly Net Income VS EBIT VS OCF VS FCFHLTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 100M -100M -200M -300M

1.2 Ratios

HLTH's Return On Assets of -109.92% is on the low side compared to the rest of the industry. HLTH is outperformed by 81.68% of its industry peers.
HLTH's Return On Equity of -149.25% is on the low side compared to the rest of the industry. HLTH is outperformed by 76.44% of its industry peers.
Industry RankSector Rank
ROA -109.92%
ROE -149.25%
ROIC N/A
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
HLTH Yearly ROA, ROE, ROICHLTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -50 -100

1.3 Margins

HLTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HLTH Yearly Profit, Operating, Gross MarginsHLTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -200 -400

6

2. Health

2.1 Basic Checks

HLTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HLTH has been increased compared to 1 year ago.
Compared to 1 year ago, HLTH has an improved debt to assets ratio.
HLTH Yearly Shares OutstandingHLTH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
HLTH Yearly Total Debt VS Total AssetsHLTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

HLTH has an Altman-Z score of -4.83. This is a bad value and indicates that HLTH is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of HLTH (-4.83) is worse than 68.59% of its industry peers.
HLTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.83
ROIC/WACCN/A
WACC9.06%
HLTH Yearly LT Debt VS Equity VS FCFHLTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

HLTH has a Current Ratio of 2.54. This indicates that HLTH is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HLTH (2.54) is comparable to the rest of the industry.
A Quick Ratio of 2.22 indicates that HLTH has no problem at all paying its short term obligations.
HLTH's Quick ratio of 2.22 is in line compared to the rest of the industry. HLTH outperforms 47.12% of its industry peers.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.22
HLTH Yearly Current Assets VS Current LiabilitesHLTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 200M 400M 600M

5

3. Growth

3.1 Past

HLTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -153.47%.
HLTH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -85.32%.
HLTH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 45.56% yearly.
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%

3.2 Future

The Earnings Per Share is expected to grow by 17.29% on average over the next years. This is quite good.
The Revenue is expected to grow by 52.69% on average over the next years. This is a very strong growth
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
HLTH Yearly Revenue VS EstimatesHLTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
HLTH Yearly EPS VS EstimatesHLTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -1 -2

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HLTH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HLTH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HLTH Price Earnings VS Forward Price EarningsHLTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HLTH Per share dataHLTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

HLTH's earnings are expected to grow with 24.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.95%
EPS Next 3Y24.25%

0

5. Dividend

5.1 Amount

HLTH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CUE HEALTH INC

NASDAQ:HLTH (6/5/2024, 8:00:01 PM)

After market: 0.0489 +0.01 (+12.67%)

0.0434

-0.02 (-29.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2024-05-13/amc
Earnings (Next)08-07 2024-08-07/amc
Inst Owners1.03%
Inst Owner Change0%
Ins Owners29.79%
Ins Owner Change0%
Market Cap6.90M
Analysts43.33
Price Target0.51 (1075.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.92%
Min EPS beat(2)-120.16%
Max EPS beat(2)6.32%
EPS beat(4)1
Avg EPS beat(4)-29.65%
Min EPS beat(4)-120.16%
Max EPS beat(4)6.32%
EPS beat(8)5
Avg EPS beat(8)14.83%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.53%
Min Revenue beat(2)2.82%
Max Revenue beat(2)4.24%
Revenue beat(4)3
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-27.41%
Max Revenue beat(4)5.48%
Revenue beat(8)7
Avg Revenue beat(8)33.33%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-33.33%
PT rev (3m)-52.94%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-46.75%
EPS NY rev (1m)0%
EPS NY rev (3m)-26.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-65.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-38.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B 0.03
P/tB 0.03
EV/EBITDA N/A
EPS(TTM)-2.56
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0.45
BVpS1.57
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -109.92%
ROE -149.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.89%
ROA(5y)-43.77%
ROE(3y)-56.89%
ROE(5y)-73.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.18%
Cap/Sales 27.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.22
Altman-Z -4.83
F-Score3
WACC9.06%
ROIC/WACCN/A
Cap/Depr(3y)177.13%
Cap/Depr(5y)371.33%
Cap/Sales(3y)19.89%
Cap/Sales(5y)88.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-153.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-357.14%
EPS Next Y56.3%
EPS Next 2Y31.95%
EPS Next 3Y24.25%
EPS Next 5Y17.29%
Revenue 1Y (TTM)-85.32%
Revenue growth 3Y45.56%
Revenue growth 5YN/A
Sales Q2Q%-87.19%
Revenue Next Year-18.38%
Revenue Next 2Y25.41%
Revenue Next 3Y43.74%
Revenue Next 5Y52.69%
EBIT growth 1Y-45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.74%
EBIT Next 3Y13.08%
EBIT Next 5Y20.63%
FCF growth 1Y9.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.13%
OCF growth 3YN/A
OCF growth 5YN/A